Table 1.
Monoclonal Antibodies Targeting the CGRP Pathway in Phase 3 Clinical Studies
| Primary Sponsoring Company | INN or Code Name | Molecular Format | Target | Most Advanced Phase | Indications |
|---|---|---|---|---|---|
| Alder Biopharmaceuticals | ALD403/eptinezumab | Humanized IgG1 | CGRP | Phase 3 | Migraine prevention |
| Eli Lilly and Company | LY2951742/galcanezumab | Humanized IgG4 | CGRP | Phase 3 | Migraine and cluster headache prevention |
| Teva Pharmaceuticals | TEV‐48125/frestanezumab | Humanized IgG2 | CGRP | Phase 3 | Migraine prevention |
| Amgen/Novartis | AMG 334/erenumab | Human IgG2 | CGRP receptor | Phase 3 | Migraine prevention |
INN, international nonproprietary name; CGRP, calcitonin gene–related peptide.